Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-176 in Advanced NSCLC After EGFR TKI Failure
NCT04820023Phase 2Terminated
- Sponsor
- Bridge Biotherapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of BBT-176 in non-small cell lung cancer (NSCLC), sponsored by Bridge Biotherapeutics. Started Apr 2021; status: terminated.
02
Drugs
BBT-176
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04820023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820023.